Markus Warmuth, Monte Rosa Therapeutics CEO
May 21, 2024 10:35 AM EDT
Financing

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

Monte Rosa Ther­a­peu­tics CEO Markus War­muth ex­pects mol­e­c­u­lar glues to make up a new class of drugs with “al­most un­lim­it­ed po­ten­tial” in the long run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times